Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
3.905
+0.065 (1.69%)
At close: Aug 1, 2025, 4:00 PM
3.950
+0.045 (1.15%)
After-hours: Aug 1, 2025, 4:24 PM EDT
Myriad Genetics Stock Forecast
Stock Price Forecast
The 14 analysts that cover Myriad Genetics stock have a consensus rating of "Hold" and an average price target of $15.14, which forecasts a 287.71% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $30.
Price Target: $15.14 (+287.71%)
Analyst Consensus: Hold
* Price targets were last updated on May 21, 2025.
Analyst Ratings
The average analyst rating for Myriad Genetics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 4 | 4 | 2 | 2 | 2 |
| Hold | 6 | 6 | 7 | 9 | 9 | 9 |
| Sell | 3 | 3 | 3 | 3 | 3 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 15 | 16 | 16 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy → Hold Downgrades $20 → $6 | Buy → Hold | Downgrades | $20 → $6 | +53.65% | May 21, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $13 → $9 | Buy | Maintains | $13 → $9 | +130.47% | May 15, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $22 → $6 | Buy → Hold | Downgrades | $22 → $6 | +53.65% | May 8, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $14 → $8 | Strong Buy | Maintains | $14 → $8 | +104.87% | May 7, 2025 |
| UBS | UBS | Hold Maintains $16 → $7 | Hold | Maintains | $16 → $7 | +79.26% | May 7, 2025 |
Financial Forecast
Revenue This Year
826.41M
from 837.60M
Decreased by -1.34%
Revenue Next Year
881.31M
from 826.41M
Increased by 6.64%
EPS This Year
-0.01
from -1.41
EPS Next Year
0.16
from -0.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 859.1M | 939.8M | 1.0B | |
| Avg | 826.4M | 881.3M | 944.6M | |
| Low | 769.6M | 784.2M | 807.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 2.6% | 13.7% | 17.8% | |
| Avg | -1.3% | 6.6% | 7.2% | |
| Low | -8.1% | -5.1% | -8.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | 0.01 | 0.41 | 0.67 | |
| Avg | -0.01 | 0.16 | 0.33 | |
| Low | -0.05 | -0.05 | 0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2029 |
|---|---|---|---|---|
| High | - | - | 331.5% | |
| Avg | - | - | 112.8% | |
| Low | - | - | -25.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.